Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

MDR Inhibitors for Anticancer Therapy

Author(s): Peter Werner and Andreas Hilgeroth*

Volume 22, Issue 7, 2022

Published on: 22 September, 2021

Page: [1242 - 1243] Pages: 2

DOI: 10.2174/1871520621666210922112404

conference banner
« Previous Next »
[1]
Gupta, S.K.; Singh, P.; Ali, V.; Verma, M. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncol. Rev., 2020, 14(2), 448.
[http://dx.doi.org/10.4081/oncol.2020.448] [PMID: 32676170]
[2]
Baguley, B.C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol., 2010, 46(3), 308-316.
[http://dx.doi.org/10.1007/s12033-010-9321-2] [PMID: 20717753]
[3]
Hamed, A.R.; Abdel-Azim, N.S.; Shams, K.A.; Hammouda, F.M. Targeting multidrug resistance in cancer by natural chemosensitizers. Bull. Natl. Res. Cent., 2019, 43, 8.
[http://dx.doi.org/10.1186/s42269-019-0043-8]
[4]
Türk, D.; Hall, M.D.; Chu, B.F.; Ludwig, J.A.; Fales, H.M.; Gottesman, M.M.; Szakács, G. Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res., 2009, 69(21), 8293-8301.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2422] [PMID: 19843850]
[5]
Stefan, S.M. Multi-target ABC transporter modulators: What next and where to go? Future Med. Chem., 2019, 11(18), 2353-2358.
[http://dx.doi.org/10.4155/fmc-2019-0185] [PMID: 31516029]
[6]
Kim, C.W.; Asai, D.; Kang, J-H.; Kishimura, A.; Mori, T.; Katayama, Y. Reversal of efflux of an anticancer drug in human drug-resistant breast cancer cells by inhibition of protein kinase Cα (PKCα) activity. Tumour Biol., 2016, 37(2), 1901-1908.
[http://dx.doi.org/10.1007/s13277-015-3963-4] [PMID: 26323260]
[7]
Jaramillo, A.C.; Saig, F.A.; Cloos, J.; Jansen, G.; Peters, G.J. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance. Cancer Drug Resist., 2018, 1, 6-29.
[http://dx.doi.org/10.20517/cdr.2018.02]
[8]
Klinkhammer, W.; Müller, H.; Globisch, C.; Pajeva, I.K.; Wiese, M. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators. Bioorg. Med. Chem., 2009, 17(6), 2524-2535.
[http://dx.doi.org/10.1016/j.bmc.2009.01.072] [PMID: 19250834]
[9]
Avendano, C.; Menéndez, J.C. Drugs that modulate resistance to antitumor agents. Medicinal chemistry of anticancer drugs; Elsevier: Boston, 2015, Vol. 2, pp. 655-700.
[http://dx.doi.org/10.1016/B978-0-444-62649-3.00014-4]
[10]
Yu, M.; Ocana, A.; Tannock, I.F. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: Why has it failed to provide clinical benefit? Cancer Metastasis Rev., 2013, 32(1-2), 211-227.
[http://dx.doi.org/10.1007/s10555-012-9402-8] [PMID: 23093326]
[11]
Beretta, G.L.; Cassinelli, G.; Pennati, M.; Zuco, V.; Gatti, L. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem., 2017, 142, 271-289.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.062] [PMID: 28851502]
[12]
Tamaki, A.; Ierano, C.; Szakacs, G.; Robey, R.W.; Bates, S.E. The controversial role of ABC transporters in clinical oncology. Essays Biochem., 2011, 50(1), 209-232.
[PMID: 21967059]
[13]
Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer, 2018, 18(7), 452-464.
[http://dx.doi.org/10.1038/s41568-018-0005-8] [PMID: 29643473]
[14]
Liu, B.; Li, L-J.; Gong, X.; Zhang, W.; Zhang, H.; Zhao, L. Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myeloid leukemia. Oncol. Lett., 2018, 15(5), 6671-6677.
[http://dx.doi.org/10.3892/ol.2018.8095] [PMID: 29616130]
[15]
Döring, H.; Kreutzer, D.; Ritter, C.; Hilgeroth, A. Discovery of novel symmetrical 1,4-dihydropyridines as inhibitors of multidrug-ressitant protein (MRP4) efflux pump for anticancer therapy. Molecules, 2021, 26, 18.
[http://dx.doi.org/10.3390/molecules26010018]
[16]
Kreutzer, D.; Döring, H.; Werner, P.; Ritter, C.A.; Hilgeroth, A. Novel symmetrical cage compounds as inhibitors of the symmetrical MRP4-efflux pump for anticancer therapy. Int. J. Mol. Sci., 2021, 22(10), 5098.
[http://dx.doi.org/10.3390/ijms22105098] [PMID: 34065900]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy